232 results
8-K
EX-3.2
CTIC
CTI BioPharma Corp
26 Jun 23
Termination of a Material Definitive Agreement
8:51am
office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal as hereinafter provided.
Section 3.3 … elected and qualified or until his or her earlier death, resignation or removal as herein provided.
Section 3.5 Annual Meetings. The annual meeting of each
SC 14D9
CTIC
CTI BioPharma Corp
25 May 23
Tender offer solicitation
7:00am
is terminated by CTI without Cause (as defined in the agreement), due to his death or Disability or by him for Good Reason (as defined in the agreement) or CTI … , or for Dr. Craig, due to his death or disability or if CTI chooses not to renew Dr. Craig’s employment, in each case, immediately following the Closing:
Name
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
survive the death or incapacity of the undersigned, and any obligation of the undersigned hereunder shall be binding upon the heirs, executors
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
a termination for “cause” or due to the employee’s death or disability, or hire any employee with a title of senior vice president or above;
adopt or implement
SC14D9C
EX-2.1
CTIC
CTI BioPharma Corp
10 May 23
Written communication relating to third party tender offer
1:30pm
and qualified, as the case may be, or their earlier death, resignation or removal.
2.5 Conversion of Shares.
(a) Subject to Section 2.7, at the Effective … of senior vice president or above, other than a termination for “cause” or due to the employee’s death or disability, or hire any employee with a title
SC14D9C
EX-3.1
ydkadq
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
EX-2.1
ty3myq 2z6enat66qwfr
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-3.1
bn5q3
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-99.1
aixx5 s2qkg
7 Nov 22
CTI BioPharma Reports Third Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
z2kkf07r
8 Aug 22
CTI BioPharma Reports Second Quarter 2022 Financial Results
4:08pm
8-K
EX-10.2
m4kc0b 8sehmfnu
3 Jun 22
Departure of Directors or Certain Officers
4:06pm
8-K
EX-10.1
y16srfye221lc
3 Jun 22
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
fiq2wbjhp8frmh
12 May 22
CTI BioPharma Reports First Quarter 2022 Financial Results
4:07pm
8-K
EX-10.2
06ol mzt8xcevch
4 Mar 22
Departure of Directors or Certain Officers
5:04pm
8-K
EX-99.1
qjjiikmd79fk6rlv
1 Mar 22
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
8:02pm
S-8
EX-4.1
trx4i4n4
17 Jun 21
Registration of securities for employees
4:50pm